Bergen, Norway - Reference is made to the stock exchange announcement by BerGenBio ASA (the 'Company') on 23 May 2024 regarding the Company's annual general meeting resolving to increase the Company's share capital by NOK 3.30 by issuance of 33 new shares, each with a nominal value of NOK 0.10 to ensure that the Company's total number of outstanding shares are divisible by 100 and thereby facilitate for the reverse share split in the Company resolved at the same general meeting.

The share capital increases pertaining to the new shares is now registered with the Norwegian Register of Business Enterprises. After this, the Company's new registered share capital is NOK 390,871,160 divided into 3,908,711,600 shares, each with a nominal value of NOK 0.10.

Contact:

Martin Olin

Email: ir@bergenbio.no

Rune Skeie

Email: rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO).

(C) 2024 Electronic News Publishing, source ENP Newswire